ライフサイエンスコーパス: virologic failure

1 patients who withdrew for reasons other than virologic failure).

2 an independent risk factor for clinical and virologic failure.

3 higher probability of Y181C detection after virologic failure.

4 ed with a higher risk of NNRTI resistance at virologic failure.

5 d during 1998-2006 with a primary outcome of virologic failure.

6 s; 2) for treatment changes, and 3) for each virologic failure.

7 type of resistance mutations detected after virologic failure.

8 nd types of resistance mutations detected at virologic failure.

9 after 5 months of treatment, in a context of virologic failure.

10 ications were associated with higher odds of virologic failure.

11 mL were associated with an increased risk of virologic failure.

12 alf (19 of 32) had resistance at the time of virologic failure.

13 tricitabine resistance in most patients with virologic failure.

14 27 of the remaining subjects who experienced virologic failure.

15 iscontinued treatment for reasons other than virologic failure.

16 patients who withdrew for reasons other than virologic failure.

17 was not detected among subjects experiencing virologic failure.

18 but did increase 4-12 weeks before confirmed virologic failure.

19 pies/mL were at increased risk of subsequent virologic failure.

20 subjects in the random cohort, 57 (26%) had virologic failure.

21 cts plus unselected subjects who experienced virologic failure.

22 was associated with decreased likelihood of virologic failure.

23 evirapine were independently associated with virologic failure.

24 sed before study treatment (baseline) and at virologic failure.

25 oviral therapy (baseline) and at the time of virologic failure.

26 tly at baseline but were not associated with virologic failure.

27 drug concentrations and increase the risk of virologic failure.

28 times to virologic suppression and risks of virologic failure.

29 antiretroviral therapy (ART), predict future virologic failure.

30 e performed for participants identified with virologic failure.

31 s were found in 20 of 47 patients (43%) with virologic failure.

32 ion of antiretroviral therapy and to prevent virologic failure.

33 l, Mozambique, were previously evaluated for virologic failure.

34 No patient had virologic failure.

35 pleted treatment in either study experienced virologic failure.

36 .15; 95% CI, 1.03-1.28) were associated with virologic failure.

37 in a subset of patients treated with SOF at virologic failure.

38 reappeared at relapse in all 3 patients with virologic failure.

39 0.98; 95% CI, .97-.99) decreased the risk of virologic failure.

40 ce of L159F or V321A to 2% (1 of 50 each) at virologic failure.

41 1 subtype were independently associated with virologic failure.

42 Relapse accounted for all cases of virologic failure.

43 ths, 15 (19%) follow-up losses, and 31 (38%) virologic failures.

44 virologic suppression (88%-93%), subsequent virologic failure (0.1%-0.6%/month), and Medicaid-discou

45 rologic failures (hazard ratio for the first virologic failure, 0.39; hazard ratio for the second vir

46 c failure, 0.39; hazard ratio for the second virologic failure, 0.47), as well as the failure of the

47 The cumulative incidence of virologic failure 1 year after having maintained a LLV f

48 Intermittent viremia did not predict virologic failure: 10 (10.4%) of 96 patients with and 20

49 Three participants experienced virologic failure 12, 14, and 20 weeks after simplificat

50 ce interval, 1.46 to 3.72; P<0.001), with 57 virologic failures (14%) in the abacavir-lamivudine grou

51 rom the randomly selected subcohort (51 with virologic failure, 144 without virologic failure), plus

52 Among 1186 subjects with virologic failure, 35 (3.0%) were CrAg positive with med

53 Among 1,186 subjects with virologic failure, 35 (3.0%) were CrAg-positive with med

54 d lopinavir group), and 5 died without prior virologic failure (4 in the nevirapine group and 1 in th

55 t LLV (GSS <3) had a 2.1-fold higher risk of virologic failure (95% confidence interval, 1.2- to 3.7-

56 Virologic failure (a viral load of >1000 copies per mill

57 were maintained on their study regimen after virologic failure accumulated additional Nvp and 3TC mut

58 Predictors for shorter time to virologic failure after initial suppression in multivari

59 fected with hepatitis C virus who experience virologic failure after treatment with direct-acting ant

60 95% confidence interval [CI], 1.09-4.18) and virologic failure (aHR 2.42; 95% CI, 1.33-4.41).

61 After virologic failure, all Envs acquired resistance to ENF b

62 cipients satisfied prespecified criteria for virologic failure, all with genotype 1a infection.

63 vents among white participants and decreased virologic failure among black participants.

64 One case of confirmed virologic failure and 3 cases with viral blips were dete

65 Participants with virologic failure and anticipated antiretroviral suscept

66 Virologic failure and changes in CD4 count in relation t

67 was associated with decreased likelihood of virologic failure and decreased emergence of efavirenz-r

68 Identification of virologic failure and early management mitigates the gre

69 The association between subsequent virologic failure and persistence status were estimated

70 Associations between selected covariates and virologic failure and resistance were evaluated using ge

71 copies per milliliter or more, the times to virologic failure and the first adverse event were both

72 tical or behavioral interventions to prevent virologic failure and to stimulate complete recovery of

73 avirenz and nelfinavir, and they may predict virologic failure and/or emergence of drug-resistant vir

74 Fifty-four children (49%) experienced virologic failure, and 2 (2%) died.

75 f patients with genotype 1b infection, 1 had virologic failure, and 2 did not have data available at

76 nd 3TC mutations were detected frequently at virologic failure, and Nvp mutations were more common am

77 At virologic failure, antiretroviral resistance mutations w

78 0% of the women who had received placebo had virologic failure, as compared with 18.4% of those who h

79 In contrast, participants with virologic failure assigned EFV had more RT changes, incl

80 ase in CD4 cell count, and a smaller risk of virologic failure at 12 months for atazanavir compared w

81 ess or death, and 0.91 (95% CI, .84-.99) for virologic failure at 12 months.

82 s associated with 2.5 to 3 times the risk of virologic failure at either 95% or greater or less than

83 level data were used to estimate the risk of virologic failure based on a Prentice weighted case-coho

84 ter NRTI discontinuation among those without virologic failure but did increase 4-12 weeks before con

85 V alone, of whom 30 (88%) did not experience virologic failure by 48 weeks after simplification.

86 r PI-resistance mutations were identified at virologic failure by standard genotyping or SGS.

87 rimary end point for mothers and infants was virologic failure by the 6-month visit after initiation

88 Virologic failure by the 6-month visit occurred in signi

89 ew DM diagnosis plus DM-related medication), virologic failure, cART regimen switch, administrative c

90 ART is significantly less likely to lead to virologic failure compared to NVP-based ART.

91 HLA class I alleles subsequently experienced virologic failure compared to those without protective a

92 ith detectable minority variants experienced virologic failure compared with 15% of those without min

93 with HIV-1 infection had increased rates of virologic failure, compared with efavirenz plus dual NRT

94 The primary end point was time to virologic failure (confirmed HIV-1 RNA level > or = 200

95 use of CCR5 antagonists even in the face of virologic failure could provide a relative degree of pro

96 HIV-1 RNA <50 and >=50 copies/mL, confirmed virologic failure (CVF; 2 consecutive HIV-1 RNA >=200 co

97 mL and <50 copies/mL, incidence of confirmed virologic failure (CVF; 2 consecutive measurements >=200

98 of post-ART follow-up, 19 (24%) experienced virologic failure (dapivirine: 6/32, 19%; placebo: 13/39

99 By TaqMan 2.0, virologic failure defined as HIV-1 RNA >/= 50 copies/mL

100 end point was the time from randomization to virologic failure (defined as a confirmed HIV-1 RNA leve

101 pared the cumulative incidence of subsequent virologic failure (defined as an HIV RNA viral load of >

102 Virologic failure, defined as a confirmed HIV-1 RNA leve

103 remained; however, VL monitoring and earlier virologic failure detection may result in lower NRTI res

104 une activation, indicating that a history of virologic failure does not inexorably lead to increased

105 s after NNRTI monotherapy and contributed to virologic failure during ART in 1/3 animals.

106 tly associated with higher-level resistance; virologic failure during the peginterferon/ribavirin-tre

107 Virologic failure during the telaprevir-treatment phase

108 Virologic failure during treatment and relapse after tre

109 No patients had virologic failure during treatment, and no patients had

110 Virologic failure following EFV-containing treatment was

111 HIV-1 disease progression and virologic failure following initiation of ART were asses

112 Virologic failure following treatment of hepatitis C vir

113 confirmed nonadherence as the major cause of virologic failure for 9 (45%) of 20 highly treatment-exp

114 In the low HIV RNA stratum, times to virologic failure for ABC/3TC or TDF/FTC were not differ

115 IV-1) minority variants increase the risk of virologic failure for first-line nonnucleoside reverse t

116 The adjusted relative hazard of virologic failure for patients who started nevirapine, c

117 prescribed ART for at least 6 months without virologic failure for pLLV.

118 The risk of virologic failure for subjects with baseline NNRTI resis

119 Among the nevirapine-treated children with virologic failure for whom data on resistance were avail

120 We studied 29 subjects with virologic failure from a phase IIb study of the CCR5 ant

121 Plasma samples at entry and at time of virologic failure from patients enrolled in the AIDS Cli

122 iral load suppression and time to subsequent virologic failure (>400 copies/mL).

123 ng among ART experienced Ugandan adults with virologic failure (>=1,000 copies/mL) using leftover pla

124 ng among ART-experienced Ugandan adults with virologic failure (>=1000 copies/mL) using leftover plas

125 ns were associated with an increased risk of virologic failure (hazard ratio (HR], 2.3 [95% confidenc

126 ignificantly associated with shorter time to virologic failure (hazard ratio [HR], 2.03; P = .035), a

127 to whites, blacks had an increased hazard of virologic failure (hazard ratio [HR]; 1.7; 95% confidenc

128 t regimen (hazard ratio, 0.39) and the first virologic failure (hazard ratio, 0.34).

129 .48 to 1.06), as well as to delay the second virologic failure (hazard ratio, 0.56; 95 percent confid

130 9 copies/mL for 6 months doubled the risk of virologic failure (hazard ratio, 2.22; 95% CI, 1.60-3.09

131 cantly delayed both the first and the second virologic failures (hazard ratio for the first virologic

132 Computer alerts were generated for virologic failure (HIV RNA level >400 copies/mL after a

133 /m2 has been identified as a risk factor for virologic failure; however, data are limited due to smal

134 A testing of virus from the first episode of virologic failure identified protease resistance mutatio

135 of persistent LLV on the subsequent risk of virologic failure in a cohort of people living with HIV

136 (baseline) drug resistance and subtype with virologic failure in a multinational, randomized clinica

137 ignificantly less likely than NVP to lead to virologic failure in both trials (RR 0.85 [0.73-0.99] I(

138 RNA levels from 330 subjects who experienced virologic failure in clinical trials of direct-acting an

139 nd levels of susceptibility after first-line virologic failure in individuals from Thailand, South Af

140 on with nevirapine was a strong predictor of virologic failure in our cohort, which was not explained

141 ion (Merck 035), but was not associated with virologic failure in patients receiving initial combinat

142 (1%) and was only associated with increased virologic failure in patients treated for short duration

143 Virologic failure in subtype C is characterized by high

144 sequencing were performed at baseline and at virologic failure in the 4 MK-5172 dosing arms.

145 d in two of these four animals, resulting in virologic failure in the animal with the highest level o

146 mutations were detected in participants with virologic failure in the EFV-TDF-FTC group.

147 ent adherence estimated the relative risk of virologic failure in the presence of NNRTI-resistant min

148 nts was associated with an increased risk of virologic failure in the setting of recent treatment adh

149 and V321A in 5% (17 of 353) of patients with virologic failure in the SOF studies.

150 dy was stopped because of increased rates of virologic failure in the VCV 25 mg/day arm (relative haz

151 to identify a significantly earlier time to virologic failure in women randomized to ATV/r compared

152 There were no protocol-defined virologic failures; incidences of adverse events (AEs) a

153 There were no protocol-defined virologic failures; incidences of adverse events (AEs) a

154 Three patients had D168 variants at virologic failure, including 2 with the D168A variant as

155 Ag screening is cost-effective in those with virologic failure is unknown.

156 or >=1 year in 2005-2015 were followed until virologic failure, loss to follow-up, death, or study en

157 identify high-risk individuals and to detect virologic failure may limit the effectiveness of antiret

158 high rates of sustained virologic response, virologic failure may still occur, potentially leading t

159 Of 44 ART-experienced children, 57% had virologic failure, most never virologically suppressed.

160 No virologic failure occurred during the study.

161 Confirmed virologic failure occurred in 0.8% of individuals overal

162 Virologic failure occurred in 13 (33%) of 39 and relapse

163 Virologic failure occurred in 13 patients (4%), includin

164 On-treatment virologic failure occurred in 3 patients with HCV genoty

165 Virologic failure occurred in 34 patients (8%) overall.

166 Virologic failure occurred in 37 (28 in the nevirapine g

167 Virologic failure occurred in 97 (34%) subjects: 52 (37%

168 Virologic failure occurred in no patients in arm A and i

169 Virologic failure occurred uncommonly (6/266 [2.3%]) in

170 iciency virus-infected patients experiencing virologic failure of an indinavir- or ritonavir-containi

171 iation between detected minority DRM and the virologic failure of first-line antiretroviral therapy (

172 N348I emerges frequently with virologic failure of first-line ART in subtype C HIV-1 i

173 Y181C mutants more than tripled the risk of virologic failure of first-line efavirenz-based antiretr

174 LLV has been associated with virologic failure of HAART in some studies, while in oth

175 resistant viruses from patients experiencing virologic failure of indinavir and/or nelfinavir.

176 ces in plasma obtained before therapy and at virologic failure of initial ART among 63 participants w

177 frequent occurrence of E138K/M184I after the virologic failure of rilpivirine-, lamivudine-, and emtr

178 ress viral replication even after short-term virologic failure of three-drug HAART and despite ongoin

179 xposure to both NRTI and NNRTI and confirmed virologic failure on a PI-containing regimen were requir

180 hibitors (NRTIs) and non-NRTIs and confirmed virologic failure on a protease inhibitor-containing reg

181 erall, one-third of patients who experienced virologic failure on an indinavir-containing regimen sup

182 tonavir (LPV/r) monotherapy after first-line virologic failure on an NNRTI regimen.

183 emerged frequently in patients experiencing virologic failure on antiretroviral combinations that do

184 odeficiency virus (HIV) have higher rates of virologic failure on antiretroviral therapy (ART) and of

185 -type HIV, and the proportion of people with virologic failure on dolutegravir-based antiretroviral t

186 source-limited settings, genotype testing at virologic failure on first-line antiretroviral therapy (

187 Eligible patients had virologic failure on first-line TEE.

188 n treatment-naive noncirrhotic patients with virologic failure on MK-5172 (100-800 mg/day) plus pegyl

189 eatment-experienced patients who experienced virologic failure on treatment regimens containing the C

190 .83]) and no difference in the likelihood of virologic failure or CD4 cell gain.

191 primary end point was the time to confirmed virologic failure or death.

192 iated with decreased adherence, but not with virologic failure or development of drug resistance in t

193 ritonavir-boosted lopinavir group (14%) had virologic failure or died.

194 The primary end point was virologic failure or discontinuation of treatment by stu

195 n vs a TAF-based regimen at week 48, with no virologic failure or emergent resistance reported with D

196 e until initiation of ART and the time until virologic failure or initiation of ART were similar in t

197 No virologic failure or significant NC changes were detecte

198 No virologic failure or significant NC changes were detecte

199 Blips were not associated with virologic failure or the development of drug resistance.

200 l-determined change in regimen due to either virologic failure or treatment-related toxic effects.

201 No virologic failure or vertical transmission occurred.

202 pregnancy, elimination of food restrictions, virologic failure, or drug toxicities.

203 state of viral replication (P =.03), but not virologic failure over 4.5 years of observation.

204 ts, all pairwise comparisons of incidence of virologic failure over 96 weeks showed equivalence withi

205 group and 41.7% in the nevirapine group had virologic failure (P<0.001).

206 treatment CD8(+) T cell activation predicted virologic failure (P=.046).

207 Patients experiencing virologic failure (persistent HIV RNA >500 copies RNA/mL

208 During long-term virologic failure, plasma HIV RNA levels often remained

209 200 copies/mL doubled the risk of developing virologic failure (pLLV 200-499: HR, 1.81 [95% CI, 1.08-

210 hort (51 with virologic failure, 144 without virologic failure), plus 127 of the remaining subjects w

211 cy virus (HIV)-infected women are at risk of virologic failure postpartum.

212 The regimen with the highest virologic failure rate preserved greater future drug opt

213 he SVR12 rate was 74.3% and the on-treatment virologic failure rate was 0%.

214 In the high stratum, virologic failure rate was significantly higher for ABC/

215 In contrast, virologic failure rates did not differ significantly bet

216 linded treatment in the high stratum, higher virologic failure rates were seen with ABC/3TC with EFV

217 t frequently observed resistance mutation at virologic failure regardless of the baseline minority va

218 The primary outcome measure was time to virologic failure, regardless of ART changes.

219 Primary endpoints were times to virologic failure, regimen modification, and safety even

220 45 patients without intermittent viremia had virologic failure (relative risk, 0.76; 95% confidence i

221 he outcome of treatment-which contributes to virologic failure, resistance generation and viral trans

222 Genetic analyses strongly suggest that virologic failure resulted from the reemergence of virus

223 Thirteen of these 23 (56.5%) virologic failures resuppressed after a median of 8.0 mo

224 In this analysis, blacks had a 40% higher virologic failure risk than whites that was not explaine

225 ex with 3 primary study endpoints of time to virologic failure, safety, and tolerability events were

226 given HIV RNA level measured 12 weeks after virologic failure, subsequent CD4+ T cell decline was sl

227 countries (LMICs) experience higher rates of virologic failure than adults.

228 ntiretroviral therapy show a shorter time to virologic failure than patients infected with wild-type

229 ation therapy were more likely to experience virologic failure than those who had taken amprenavir mo

230 e combined efavirenz groups (11 percent) had virologic failure; the time to virologic failure was sig

231 Among 265 participants with virologic failure, those assigned atazanavir plus ritona

232 as performed at baseline and periodically in virologic failures throughout the 24-week posttherapy fo

233 mens, respectively, reached protocol-defined virologic failure; time to virologic failure was not sig

234 HCV genotype 1-infected patients with prior virologic failure to HCV DAA-containing therapy.

235 ith the detection of R155K/D168A in NS3 from virologic failures treated with simeprevir but not grazo

236 uld be the most reliable for predicting true virologic failure using DBS.

237 Calendar trends in virologic failure (VF) among human immunodeficiency viru

238 vel (primary) and determination of confirmed virologic failure (VF) from longitudinal samples.

239 rs (INSTIs) have been reported to experience virologic failure (VF) in the absence of resistance muta

240 persistent low-level viremia (pLLV) predicts virologic failure (VF) is unclear.

241 resistant variants have been associated with virologic failure (VF) of initial NVP-based combination

242 Virologic failure (VF) on a first-line ritonavir-boosted

243 avir/ritonavir (LPV/r) monotherapy following virologic failure (VF) on first-line human immunodeficie

244 Virologic failure (VF) was defined as 2 consecutive HIV

245 Virologic failure (VF) was defined as confirmed rebound

246 ary endpoint: stopping randomized treatment, virologic failure (VF), or death by 6 months.

247 sent in 817 (56.5%) of 1445 individuals with virologic failure (VF).

248 ime from randomization to death or confirmed virologic failure ([VF]) (plasma HIV RNA<1 log(10) below

249 End points included virologic failure (viral load, >/= 400 copies/mL) and ad

250 Participants in the POC arm with confirmed virologic failure vs those in the SOC arm were switched

251 A clinical history of virologic failure was also not significantly associated

252 Virologic failure was associated most frequently with ef

253 significantly increased independent risk of virologic failure was associated with continuing a 3TC-c

254 f NNRTI and NRTI resistance after first-line virologic failure was associated with higher VL at study

255 finavir recipients, a trend toward decreased virologic failure was associated with the polymorphism C

256 Increased hazard of virologic failure was associated with younger age, highe

257 Virologic failure was defined as 2 consecutive human imm

258 Virologic failure was defined as a plasma HIV RNA level

259 Virologic failure was defined as the first of 2 consecut

260 Virologic failure was documented in 22% of patients with

261 Drug resistance at virologic failure was evaluated by standard genotyping a

262 A dose-dependent increased risk of virologic failure was found in participants with a highe

263 ents with genotype 1a infection, the rate of virologic failure was higher in the ribavirin-free group

264 Virologic failure was less likely in the efavirenz group

265 a median follow-up of 112 weeks, the time to virologic failure was longer in the efavirenz group than

266 Virologic failure was lower in the efavirenz + indinavir

267 Increased risk of virologic failure was most strongly associated with mino

268 5 (32%) of those in the calls group; time to virologic failure was not different (P=.32).

269 protocol-defined virologic failure; time to virologic failure was not significantly different (hazar

270 Over 3 years, the risk of virologic failure was not significantly different among

271 Cox proportional hazards model, the risk for virologic failure was not significantly greater in the A

272 Virologic failure was observed in 60% of cases and was a

273 Antiretroviral resistance at the time of virologic failure was rare but more frequent with ralteg

274 lanned subgroup analyses, increased risk for virologic failure was seen in non-Hispanic black patient

275 therapy was longer (P=0.05), and the time to virologic failure was shorter (P=0.05).

276 0 copies per milliliter or more, the time to virologic failure was significantly shorter in the abaca

277 percent) had virologic failure; the time to virologic failure was significantly shorter in the tripl

278 In the low HIV RNA stratum, time to virologic failure was similar for ABC/3TC vs TDF/FTC wit

279 Virologic failure was uncommon after week 48.

280 or (NNRTI)-resistant variants on the risk of virologic failure, we reanalyzed a case-cohort substudy

281 Independent predictors of higher rates of virologic failure were <95% adherence, receiving the 4-d

282 Hazard ratios for time to virologic failure were 1.13 (95% CI, 0.82 to 1.56) and 1

283 +) T-cell counts obtained after triple-class virologic failure were analyzed using generalized estima

284 RT sequences from participants with N348I at virologic failure were assayed for drug susceptibility.

285 IV-1 amino acid changes from pretreatment to virologic failure were evaluated in protease and reverse

286 Rates of virologic failure were higher without ribavirin than wit

287 Mutation patterns at virologic failure were in line with individuals failing

288 Five patients with virologic failure were in the MK-5172 100-mg arm, includ

289 load (VL) <50 copies ml(-1) and without past virologic failure were randomized (1:1) to continue oral

290 with HIV-1 RNA <50 copies/mL and no previous virologic failure were randomized (1:1, stratified by ba

291 y virus (HIV)-infected subjects experiencing virologic failure while receiving a ritonavir-containing

292 PI-naive patients designated as experiencing virologic failure while receiving ATV-containing regimen

293 Due to higher virologic failure with ABC/3TC in the high HIV RNA strat

294 Otherwise, two had virologic failure with drug resistance; four had persist

295 Women assigned to ATV/r had a higher risk of virologic failure with either nucleoside reverse transcr

296 ated with a dose-dependent increased risk of virologic failure with first-line ART.

297 Fifteen percent of patients experienced virologic failure with no known resistance mutations, wh

298 al transmission of HIV-1 had higher rates of virologic failure with subsequent nevirapine-based antir

299 s) or 24 weeks (41 patients who had previous virologic failure with telaprevir or boceprevir plus peg

300 telaprevir-treated patients had on-treatment virologic failure, with no significant difference with o